Research CombinationSexual HealthPreclinical EvidenceEducational · Not medical advice

PT-141 + Kisspeptin-10: Sexual Health

A central and upstream sexual function stack combining PT-141's direct melanocortin receptor activation for arousal with kisspeptin-10's hypothalamic stimulation of the HPG axis. PT-141 enhances sexual desire and performance at the CNS level independent of vascular mechanisms, while kisspeptin-10 drives pulsatile LH and GnRH release to support the hormonal underpinning of libido. The two peptides target sexual function at different levels of the neuroendocrine hierarchy.

Find providers carrying these compounds Get matched in 7 steps

2
Compounds: Preclinical
Evidence Level: 3
Research Refs: Sexual Health
Primary Goal

Mechanism

Compound 1Sexual Health

PT-141

Activates melanocortin receptors (MC3R/MC4R) in the hypothalamus to directly enhance sexual desire and arousal independent of hormonal levels or vascular status, serving as the primary pro-libido agent.

View compound profile →

Compound 2Sexual Health

Kisspeptin-10

Stimulates pulsatile GnRH release from the hypothalamus, driving upstream LH and FSH secretion to support endogenous sex hormone levels that form the hormonal foundation of libido and sexual function.

View compound profile →

Synergistic Effect

Dual-pathway activation

PT-141 × Kisspeptin-10

Safety Notes

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; all other uses are off-label. It can cause transient blood pressure increases lasting up to 12 hours and is contraindicated in uncontrolled hypertension or cardiovascular disease. Nausea is reported in approximately 40% of users. Kisspeptin-10 is an unapproved research compound; the combination has no formal clinical safety data.

Research References

Established

Double-blind, placebo-controlled evaluation of PT-141 (bremelanotide)

J Sex Med 2004PMID 16422864

Established

Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea

Diabetes Obes Metab 2009PMID 19531057

Established

FDA approval summary for Vyleesi (bremelanotide)

ClinicalTrials.gov NCT01382719View source

Browse all →

Melanotan II + Gonadorelin: Central & Hormonal Sexual Health
Sexual HealthPreclinical
Melanotan II is researched as a melanocortin receptor agonist with centrally mediated effects on arousal and sexual motivation through MC3R and MC4R pathways. Gonadorelin, a synthetic GnRH analog, is investigated for stimulating pulsatile LH and FSH release to support the hypothalamic-pituitary-gonadal (HPG) axis. The combination addresses sexual health through complementary central arousal signaling and hormonal baseline support.
2 peptidesView Stack →

⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.